LUPIN Lupin Q3 FY26 results (Oct–Dec 2025) and concall
Management summary
- Lupin reported a strong Q3 FY26, with revenue growing 24% YoY to INR 7,168 crores and EBITDA margin expanding to 31.1%.
- Performance was broad-based, with the US achieving record sales and India's core prescription business showing double-digit growth.
- The company secured key regulatory approvals for biosimilars and is strategically investing in complex products and specialty platforms, though Q4 margins are anticipated to be impacted by increased R&D and lower PLI benefits.
Source: Inve concall analysis and management guidance record.
Highlights
-
Total revenue of INR 7,168 crores, up 24% YoY, marking the 14th consecutive quarter of YoY growth.
-
EBITDA margin (excluding Forex and other income) expanded 27.98% YoY (681 bps) to 31.1%, reaching a new high.
-
US business achieved its highest-ever sales of USD 350 million, growing 46% YoY and 11% QoQ on constant currency basis, driven by new products like Tolvaptan and Risperdal Consta®.
-
India's core prescription business grew 10.9% YoY, with the chronic segment increasing its share to 67% of the portfolio.
What they filed
Q3 FY26: revenue up 7.0%, net profit down 27.1% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 4,208 | 4,486 | 5,709 | 4,068 | 4,501 +7% |
| EBITDA | 1,411 | 1,746 | 2,730 | 1,176 | 1,617 +15% |
| Net profit | 985 | 1,291 | 2,128 | 1,357 | 717 −27% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Profitability
R&D Spend (% of Sales) Profitability · Full Year FY26 · High confidence 7.5% - 8.5%
EBITDA Margins Profitability · Full Year FY26 · High confidence 27% to 28%
Previously 25% to 26% → 27% to 28%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2US business outlook after Tolvaptan and Mirabegron tapering Direct
We're very pleased that we have Mirabegron as a material contributor in the next two years, as well as hopefully Tolvaptan also continues... Having said that we have multiple new product launches planned over the next couple of years. In particular, on the Injectables front, some
Addresses investor concerns about sustainability of US revenue post-exclusivity periods for key products, highlighting new growth drivers.
Asked by Nikhil Mathur
Accounting for Mirabegron settlement payment Direct
USD 15 million is essentially what relates to the past, whilst USD 75 million is linked to, in fact, the future and we being in the market that's the reason why it's only USD 15 million at this stage. The balance USD 75 million will be spread over to September '27... It actually
Clarifies the financial impact and accounting treatment of the significant Mirabegron settlement, distinguishing between immediate provision and future amortization.
Asked by Bino Pathiparampil
Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 5 risks, concerns & management red flags
- 5 watchlist triggers for Q4 FY26
- +7 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





